Abstract
Objective
Radiolabeled receptor-specific somatostatin analogs labeled with gamma- or beta-emitting radionuclides are useful for scintigraphic imaging and/or therapy of selected neuroendocrine tumors. However, significant renal uptake may result in radiotoxicological injury of the kidney and can limit clinical application of the agents. The aim of the study was to analyze renal handling, rate, and mechanism of renal accumulation of two somatostatin receptor-targeted peptides, [DOTA0, Tyr3, Thr8]-octreotide (DOTA-TATE) and [DOTA0, 1-Nal3]-octreotide (DOTA-NOC), labeled with indium-111 using in vitro methods.
Methods
The perfused rat kidney and freshly isolated rat renal cells were used as experimental models. The perfusion was performed in a recirculation regimen at constant pressure with solution containing bovine albumin, erythrocytes, and a mixture of essential substrates. The renal cells were isolated from rat kidneys using two-phase collagenase perfusion. Accumulation studies were used to evaluate the renal uptake of the peptides and to compare their accumulation with that of passively or actively transported model drugs. The influence of selected inhibitors of receptor-mediated endocytosis and the inhibition of energy-dependent transport processes on the uptake were also investigated using isolated renal cells.
Results
The renal clearance of 111In-DOTA-NOC in the perfused rat kidney was significantly lower than that of 111In-DOTA-TATE. Reverse situation was found in the case of renal retention. Pretreatment of the perfused kidney with maleate markedly decreased the renal retention. 111In-DOTA-NOC was accumulated in the isolated renal cells at a higher rate than 111In-DOTA-TATE (ratio 3: 1). The uptake of the radiopeptides in renal cells was higher than the uptake of not only the passively transported sucrose but also actively transported and accumulated methylglucose. The rank order of potency to inhibit the uptake by active endocytosis was approximately aprotinin > maleate > lysine. The uptake of the radiopeptides in the renal cells was temperature dependent.
Conclusions
Both in vitro methods showed a higher renal accumulation of 111In-DOTA-NOC in comparison with 111In-DOTA-TATE. The renal uptake was partly decreased by inhibitors of receptor-mediated endocytosis and by a block of energy-dependent processes. A significant participation of active transport processes in renal accumulation of the studied peptides was confirmed.
Article PDF
Similar content being viewed by others
References
Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555–1565.
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002;57:749–763.
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors: peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21:111–129.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731.
De Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, and Hofl LJ, et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437–441.
Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561–1569.
Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–1347.
De Jong M, Valdema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32:133–140.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:23–34.
Boerman OC, Wim JG, Corstens FHM. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 2001;28:1447–1449.
Cybulla M, Weiner SM, Otte A. End stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552–1554.
Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847–851.
Hammond PJ, Wade AF, Gwillian ME, Peters AM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437–1439.
De Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388–1392.
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201–212.
De Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 2005;46:1696–1700.
Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32:1136–1143.
Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 2007;34:1854–1860.
Trejtnar F, Laznicek M, Laznickova A. Pharmacokinetics of 99mTc-DTPMP as compared to 99mTc-MDP in the rat. Pharm Pharmacol Lett 1998;8:112–114.
Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1956;1:470–474.
Laznickova A, Laznicek M, Kvetina J, Drobnik J. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats. Cancer Chemother Pharmacol 1986;17:133–136.
Jones DP, Sundby GB, Ormstad K, Orrenius S. Use of isolated kidney cells for study of drug metabolism. Biochem Pharmacol 1979;28:929–935.
Boogaard PJ, Mulder GJ, Nagelkerke JF. Isolated proximal tubular cells from rat kidney as an in vitro model for studies on nephrotoxicity: I. An improved method for preparation of proximal tubular cells and their functional characterization by alpha-methylglucose uptake. Toxicol Appl Pharmacol 1989;101:135–143.
Blaufox MD. Transport of 99mTc-MAG3 via rat renal organic anion. J Nucl Med 2004;45:86–88.
Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:761–768.
Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki KH, Akizawa H, et al. Distribution and elimination characteristics of 111In-DTPA-D-Phe1-octreotide and 111In- DTPA-L-Phe1-octreotide in rats. Eur J Drug Metab Pharmacokinet 2002;27:37–43.
Melis M, Krenning EP, Bernard BF, de Visser M, Rolleman E, de Jong M. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nucl Med Biol 2007;34:633–641.
Trejtnar F, Laznicek M, Laznickova A, Mather SJ. Pharmacokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med 2000;1:177–182.
Kopecky M, Semecky V, Trejtnar F, Laznicek M, Laznickova A, Nachtigal P, et al. Analysis of accumulation of 99mTcoctreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. Nucl Med Biol 2004;31:231–239.
Kopecky M, Trejtnar F, Laznicek M, Laznickova A, Semecky V, Maina T, et al. 99mTc-demotate 1: biodistribution and elimination characteristics in rats. Nucl Med Commun 2005;26:549–554.
Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, et al. [99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate. Eur J Nucl Med Mol Imaging 2006;33:831–840.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–282.
Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, et al. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl Med Biol 2004;31:21–30.
Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals. J Nucl Med 1997;38:829.
Barone R, Van Der Smissen P, Devuyst O, Beaujean V, Pauwels S, Courtoy PJ, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int 2005;67:969–976.
Christensen EI, Nielsen R. Role of megalin and cubilin in renal physiology and pathophysiology. Rev Physiol Biochem Pharmacol 2007;158:1–22.
Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. Clin Endocrinol Metab 1993;77:1323–1328.
Balster DA, O’Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001;280:F457–F465.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trejtnar, F., Novy, Z., Petrik, M. et al. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111. Ann Nucl Med 22, 859–867 (2008). https://doi.org/10.1007/s12149-008-0192-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-008-0192-6